Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Cash & Current Investments (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Cash & Current Investments for 14 consecutive years, with $30.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Current Investments rose 47.2% to $30.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $30.0 million, a 47.2% increase, with the full-year FY2025 number at $31.0 million, up 54.71% from a year prior.
  • Cash & Current Investments was $30.0 million for Q4 2025 at Aytu Biopharma, down from $32.6 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $50.2 million in Q2 2021 to a low of $18.2 million in Q1 2025.
  • A 5-year average of $28.0 million and a median of $25.7 million in 2022 define the central range for Cash & Current Investments.
  • Peak YoY movement for Cash & Current Investments: tumbled 61.4% in 2022, then skyrocketed 62.27% in 2025.
  • Aytu Biopharma's Cash & Current Investments stood at $35.3 million in 2021, then plummeted by 32.5% to $23.8 million in 2022, then decreased by 3.47% to $23.0 million in 2023, then dropped by 11.26% to $20.4 million in 2024, then skyrocketed by 47.2% to $30.0 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Cash & Current Investments are $30.0 million (Q4 2025), $32.6 million (Q3 2025), and $31.0 million (Q2 2025).